Zapping liver cancer: electric pulses target tumors, spare healthy tissue
NCT ID NCT07192731
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a procedure called irreversible electroporation (IRE), which uses short electrical pulses to kill liver cancer cells while leaving nearby healthy tissue unharmed. It is for people with early-stage liver cancer (HCC) who have good liver function. The goal is to see if IRE can completely destroy tumors after 6 months, offering a less invasive alternative to surgery or heat-based ablation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Irreversible electroporation (IRE) device (Nanoknife)
What this could lead to
If successful, this could offer a targeted, non-surgical option to destroy liver tumors while sparing healthy tissue, potentially controlling liver cancer without major side effects.
What could go wrong
This is an early-stage, small study (50 people) with no comparison group, so results may not apply widely. The procedure carries risks like bleeding or infection, and it may not fully eradicate tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Manchester Royal Infirmiary
Manchester, M13 9WL, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••